Article
Oncology
Joe Yeong, Huey Yew Jeffrey Lum, Chong Boon Teo, Benjamin Kye Jyn Tan, Yiong Huak Chan, Ryan Yong Kiat Tay, Joan Rou-En Choo, Anand D. Jeyasekharan, Qing Hao Miow, Lit-Hsin Loo, Wei Peng Yong, Raghav Sundar
Summary: Our study showed that PD-L1 CPS scores and positivity rates are higher with the 28-8 assay compared to the 22C3 and other assays in GC PD-L1 IHC. Therefore, caution should be exercised in considering these assays as equivalent until stronger evidence of inter-assay concordance is established.
Review
Immunology
Xuan Zhao, Yulin Bao, Bi Meng, Zijian Xu, Sijin Li, Xu Wang, Rui Hou, Wen Ma, Dan Liu, Junnian Zheng, Ming Shi
Summary: Developing biomarkers for predicting the efficacy of immune checkpoint inhibitor therapies is important for avoiding side effects and economic burden. Current assays evaluating PD-L1 expression are imperfect, but recent studies are advancing the methodologies to improve accuracy. This includes standardization of immunohistochemistry tests and the use of novel in vivo probes and liquid biopsy. Considering PD-L1 expression on non-tumor cells and utilizing artificial intelligence can further enhance the predictive accuracy of PD-L1 as a biomarker.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Kimberly M. Burcher, Jeffrey W. Lantz, Elena Gavrila, Arianne Abreu, Jack T. Burcher, Andrew T. Faucheux, Amy Xie, Clayton Jackson, Alexander H. Song, Ryan T. Hughes, Thomas Lycan, Paul M. Bunch, Cristina M. Furdui, Umit Topaloglu, Ralph T. B. D'Agostino, Wei Zhang, Mercedes Porosnicu
Summary: This study evaluated tumor mutational burden and programmed death ligand-1 measurements in relation to demographics, outcomes, and response to immunotherapy in head and neck squamous cell carcinoma. The results aim to lay the groundwork for predicting individual responses to immune checkpoint inhibitors.
Article
Oncology
Richard S. P. Huang, Karthikeyan Murugesan, Meagan Montesion, Dean C. Pavlick, Douglas A. Mata, Matthew C. Hiemenz, Brennan Decker, Garrett Frampton, Lee A. Albacker, Jeffrey S. Ross
Summary: The study analyzed a large cohort of solid tumor cases to investigate CD274 copy-number changes and their correlation with PD-L1 protein expression. The prevalence of CD274 copy-number changes varied across different tumor types and was found to be significantly associated with PD-L1 positivity in certain tumor types, indicating its potential as a biomarker for immune checkpoint inhibitor therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Richard S. P. Huang, Brennan Decker, Karthikeyan Murugesan, Matthew Hiemenz, Douglas A. Mata, Gerald Li, James Creeden, Shakti H. Ramkissoon, Jeffrey S. Ross
Summary: The study found low prevalence of non-amplification short variants (SV) mutations in CD274, with mutation types and rates varying by tumor type. Specific mutation types may affect the expression level of PD-L1 protein and potentially function as resistance biomarkers in ICPI therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Vaia Florou, Charalampos S. Floudas, Asaf Maoz, Abdul Rafeh Naqash, Carter Norton, Aik Choon Tan, Ethan S. Sokol, Garrett Frampton, Heloisa P. Soares, Sonam Puri, Umang Swami, Breelyn Wilky, Peter Hosein, Jonathan Trent, Gilberto de Lima Lopes, Wungki Park, Ignacio Garrido-Laguna
Summary: This study found that frameshift mutations (FSs) can serve as a predictive biomarker for immunotherapy response in solid tumors with microsatellite stability and low tumor mutational burden (TMB).
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Jaeyun Jung, You Jeong Heo, Sehhoon Park
Summary: TMB status was analyzed using the TSO500 assay, and TMB-H was observed in 14.7% of the pan-cancer population. The study found that TMB-H patients had a higher response rate to anti-PD-(L)1 therapy, especially in gastric cancer, cholangiocarcinoma, melanoma, etc. Furthermore, patients with TMB >= 16 mut/Mb had prolonged survival after anti-PD-(L)1 therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
M. Kossai, N. Radosevic-Robin, F. Penault-Llorca
Summary: Immunotherapy for breast cancer still faces challenges in patient selection and biomarker identification, with only PD-L1 expression and mismatch repair deficiency status approved for PD-1/PD-L1 inhibitors. Ongoing research is focusing on finding additional predictive biomarkers, including immune gene signatures and tumor-infiltrating lymphocytes, to improve treatment efficacy. Dynamic assessment of treatment response through biomarkers like circulating PD-L1 and immune cell quantity, as well as consideration of host factors like microbiome and lifestyle, are important for integrating immunomodulating therapies into breast cancer management.
Article
Oncology
David Hsiehchen, Magdalena Espinoza, Cristina Valero, Chul Ahn, Luc G. T. Morris
Summary: The FDA approval of immune checkpoint inhibitors for cancers with tumor mutation burden of at least 10 mut/Mb is predicted to reduce healthcare disparities by broadening treatment eligibility. Lowering TMB thresholds can increase the eligibility of minority patients for immune checkpoint inhibitors while maintaining the predictive value of treatment benefit. This study shows variations in TMB-high cancers between racial groups and offers guidance in developing more rational eligibility criteria for immune checkpoint inhibitors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Pharmacology & Pharmacy
Jinhua Liu, Zichao Chen, Yaqun Li, Wenjie Zhao, JiBiao Wu, Zhen Zhang
Summary: Programmed death protein 1 (PD1) is an important immune checkpoint on T cells that plays a crucial role in downregulating the immune system and promoting self-tolerance, while its ligand, programmed cell death ligand 1 (PDL1), is overexpressed in malignant tumor cells, contributing to immune evasion and treatment failure. Despite the clinical efficacy of PD1/PDL1 inhibitors in many tumors, some patients may develop drug resistance, highlighting the need for further research into improving targeted therapies and understanding the associated safety issues.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Joel R. Garbow, Tanner M. Johanns, Xia Ge, John A. Engelbach, Liya Yuan, Sonika Dahiya, Christina I. Tsien, Feng Gao, Keith M. Rich, Joseph J. H. Ackerman
Summary: The study showed that previous radiation can lead to aggressive tumor growth and decreased response to PD-L1 therapy in a mouse model. The (RIM)-M-2 model highlights the impact of radiation on subsequent tumor growth and immunotherapy response, emphasizing the need for further investigation into the effects of radiation on therapeutic efficacy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cell Biology
Congkuan Song, Zhiquan Wu, Qingwen Wang, Yujin Wang, Zixin Guo, Sheng Li, Weidong Hu
Summary: A study identified two genes that can predict response to immunotherapy in lung adenocarcinoma patients, developed a signature to distinguish high- and low-risk patients, and constructed a nomogram by combining immune prognostic signature with clinical features.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Sen Yan, Han Zeng, Kaifeng Jin, Fei Shao, Zhaopei Liu, Yuan Chang, Yiwei Wang, Yu Zhu, Zewei Wang, Le Xu, Jiejie Xu
Summary: The expression of NKG2A and PD-L1 together can be used as a combinatorial biomarker to predict the therapeutic response to immune checkpoint blockade in patients with muscle-invasive bladder cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Oncology
R. Zou, Y. Wang, F. Ye, X. Zhang, M. Wang, S. Cui
Summary: PD-1/PD-L1 blockade has shown significant clinical efficacy in treating tumors, but primary and acquired resistance remain challenges. Emerging research suggests that the gut microbiome may play a role in modulating the efficacy of PD-1/PD-L1 inhibition.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2021)
Review
Medicine, General & Internal
Dahui Yu, Chong Yuan, Hedan Zhang, Wenyan Chu
Summary: This meta-analysis assessed the relationship between tumor mutation burden (TMB) and the efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer (NSCLC) patients. The findings suggest that NSCLC patients with high TMB may benefit from immunotherapy, although TMB failed to predict overall survival benefits.
Article
Oncology
Leena Gandhi, Sai-Hong Ignatius Ou, Alice T. Shaw, Fabrice Barlesi, Anne-Marie C. Dingemans, Dong-Wan Kim, D. Ross Camidge, Brett G. M. Hughes, James C. -H. Yang, Javier de Castro, Lucio Crino, Herve Lena, Pascal Do, Sophie Golding, Walter Bordogna, Ali Zeaiter, Ahmed Kotb, Shirish Gadgeel
EUROPEAN JOURNAL OF CANCER
(2017)
Article
Oncology
James Chih-Hsin Yang, Sai-Hong Ignatius Ou, Luigi De Petris, Shirish Gadgeel, Leena Gandhi, Dong-Wan Kim, Fabrice Barlesi, Ramaswamy Govindan, Anne-Marie C. Dingemans, Lucio Crino, Nerve Lena, Sanjay Popat, Jin Seok Ahn, Eric Dansin, Sophie Golding, Walter Bordogna, Bogdana Batas, Peter N. Morcos, Ali Zeaiter, Alice T. Shaw
JOURNAL OF THORACIC ONCOLOGY
(2017)
Article
Oncology
Luke R. G. Pike, Andrew Bang, Patrick Ott, Tracy Balboni, Allison Taylor, Paul Catalano, Bhupendra Rawal, Alexander Spektor, Monica Krishnan, Daniel Cagney, Brian Alexander, Ayal A. Aizer, Elizabeth. Buchbinder, Mark Awad, Leena Gandhi, F. Stephen Hodi, Jonathan D. Schoenfeld
RADIOTHERAPY AND ONCOLOGY
(2017)
Article
Medicine, General & Internal
L. Gandhi, D. Rodriguez-Abreu, S. Gadgeel, E. Esteban, E. Felip, F. De Angelis, M. Domine, P. Clingan, M. J. Hochmair, S. F. Powell, S. Y. -S. Cheng, H. G. Bischoff, N. Peled, F. Grossi, R. R. Jennens, M. Reck, R. Hui, E. B. Garon, M. Boyer, B. Rubio-Viqueira, S. Novello, T. Kurata, J. E. Gray, J. Vida, Z. Wei, J. Yang, H. Raftopoulos, M. C. Pietanza, M. C. Garassino
NEW ENGLAND JOURNAL OF MEDICINE
(2018)
Article
Oncology
Julie R. Brahmer, Ramaswamy Govindan, Robert A. Anders, Scott J. Antonia, Sarah Sagorsky, Marianne J. Davies, Steven M. Dubinett, Andrea Ferris, Leena Gandhi, Edward B. Garon, Matthew D. Hellmann, Fred R. Hirsch, Shakuntala Malik, Joel W. Neal, Vassiliki A. Papadimitrakopoulou, David L. Rimm, Lawrence H. Schwartz, Boris Sepesi, Beow Yong Yeap, Naiyer A. Rizvi, Roy S. Herbst
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2018)
Article
Oncology
Hossein Borghaei, Corey J. Langer, Shirish Gadgeel, Vassiliki A. Papadimitrakopoulou, Amita Patnaik, Steven F. Powell, Ryan D. Gentzler, Renato G. Martins, James P. Stevenson, Shadia I. Jalal, Amit Panwalkar, James Chih-Hsin Yang, Matthew Gubens, Lecia V. Sequist, Mark M. Awad, Joseph Fiore, Sanatan Saraf, Steven M. Keller, Leena Gandhi
JOURNAL OF THORACIC ONCOLOGY
(2019)
Article
Oncology
Alison M. Schram, Leena Gandhi, Monica M. Mita, Lars Damstrup, Frank Campana, Manuel Hidalgo, Enrique Grande, David M. Hyman, Rebecca S. Heist
BRITISH JOURNAL OF CANCER
(2018)
Article
Oncology
Matthew A. Gubens, Lecia V. Sequist, James P. Stevenson, Steven F. Powell, Liza C. Villaruz, Shirish M. Gadgeel, Corey J. Langer, Amita Patnaik, Hossein Borghaei, Shadia I. Jalal, Joseph Fiore, Sanatan Saraf, Harry Raftopoulos, Leena Gandhi
Article
Oncology
Martin H. Voss, Cinta Hierro, Rebecca S. Heist, James M. Cleary, Funda Meric-Bernstam, Josep Tabernero, Filip Janku, Leena Gandhi, A. John Iafrate, Darrell R. Borger, Nobuya Ishii, Youyou Hu, Yulia Kirpicheva, Valerie Nicolas-Metral, Anna Pokorska-Bocci, Anne Vaslin Chessex, Claudio Zanna, Keith T. Flaherty, Jose Baselga
CLINICAL CANCER RESEARCH
(2019)
Review
Oncology
Stefan Zimmerman, Arundhati Das, Shuhang Wang, Ricklie Julian, Leena Gandhi, Juergen Wolf
JOURNAL OF THORACIC ONCOLOGY
(2019)
Article
Oncology
David Spigel, Robert Jotte, John Nemunaitis, Merrill Shum, Jeffrey Schneider, Jerome Goldschmidt, Jennifer Eisenstein, David Berz, Lasika Seneviratne, Matei Socoteanu, Viralkumar Bhanderi, Kartik Konduri, Meng Xia, Hong Wang, Rebecca R. Hozak, Ivelina Gueorguieva, David Ferry, Leena Gandhi, Bo H. Chao, Igor Rybkin
Summary: The combination of Pegilodecakin with checkpoint inhibitors did not show improvement in objective response rate, progression-free survival, or overall survival in first-line/second-line NSCLC. Furthermore, there was an overall higher toxicity with the combination therapy compared to checkpoint inhibitors alone, leading to a higher rate of treatment discontinuation due to adverse events.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Oncology
Sai-Hong Ignatius Ou, Mark A. Socinski, Shirish Gadgeel, Leena Gandhi, Howard West, Alberto Alejandro Chiappori, Victor Cohen, Gregory J. Riely, Vlatka Smoljanovic, Walter Bordogna, Elaine Wright, Kendra Debusk, Ali Zeaiter, Alice T. Shaw
Review
Pathology
Shona Hendry, Roberto Salgado, Thomas Gevaert, Prudence A. Russell, Tom John, Bibhusal Thapa, Michael Christie, Koen van de Vijver, M. V. Estrada, Paula I. Gonzalez-Ericsson, Melinda Sanders, Benjamin Solomon, Cinzia Solinas, Gert G. G. M. Van den Eynden, Yves Allory, Matthias Preusser, Johannes Hainfellner, Giancarlo Pruneri, Andrea Vingiani, Sandra Demaria, Fraser Symmans, Paolo Nuciforo, Laura Comerma, E. A. Thompson, Sunil Lakhani, Seong-Rim Kim, Stuart Schnitt, Cecile Colpaert, Christos Sotiriou, Stefan J. Scherer, Michail Ignatiadis, Sunil Badve, Robert H. Pierce, Giuseppe Viale, Nicolas Sirtaine, Frederique Penault-Llorca, Tomohagu Sugie, Susan Fineberg, Soonmyung Paik, Ashok Srinivasan, Andrea Richardson, Yihong Wang, Ewa Chmielik, Jane Brock, Douglas B. Johnson, Justin Balko, Stephan Wienert, Veerle Bossuyt, Stefan Michiels, Nils Ternes, Nicole Burchardi, Stephen J. Luen, Peter Savas, Frederick Klauschen, Peter H. Watson, Brad H. Nelson, Carmen Criscitiello, Sandra O'Toole, Denis Larsimont, Roland de Wind, Giuseppe Curigliano, Fabrice Andre, Magali Lacroix-Triki, Mark van de Vijver, Federico Rojo, Giuseppe Floris, Shahinaz Bedri, Joseph Sparano, David Rimm, Torsten Nielsen, Zuzana Kos, Stephen Hewitt, Baljit Singh, Gelareh Farshid, Sibylle Loibl, Kimberly H. Allison, Nadine Tung, Sylvia Adams, Karen Willard-Gallo, Hugo M. Horlings, Leena Gandhi, Andre Moreira, Fred Hirsch, Maria V. Dieci, Maria Urbanowicz, Iva Brcic, Konstanty Korski, Fabien Gaire, Hartmut Koeppen, Amy Lo, Jennifer Giltnane, Marlon C. Rebelatto, Keith E. Steele, Jiping Zha, Kenneth Emancipator, Jonathan W. Juco, Carsten Denkert, Jorge Reis-Filho, Sherene Loi, Stephen B. Fox
ADVANCES IN ANATOMIC PATHOLOGY
(2017)
Review
Pathology
Shona Hendry, Roberto Salgado, Thomas Gevaert, Prudence A. Russell, Tom John, Bibhusal Thapa, Michael Christie, Koen van de Vijver, M. V Estrada, Paula I Gonzalez-Ericsson, Melinda Sanders, Benjamin sss Solomon, Cinzia Solinas, Gert G. G. M. Van den Eynden, Yves Allory, Matthias Preusser, Johannes Hainfellner, Giancarlo Pruneri, Andrea Vingiani, Sandra Demaria, Fraser Symmans, Paolo Nuciforo, Laura Comerma, E. A. Thompson, Sunil Lakhani, Seong-Rim Kim, Stuart Schnitt, Cecile Colpaert, Christos Sotiriou, Stefan J. Scherer, Michail Ignatiadis, Sunil Badve, Robert H. Pierce, Giuseppe Viale, Nicolas Sirtaine, Frederique Penault-Llorca, Tomohagu Sugie, Susan Fineberg, Soonmyung Paik, Ashok Srinivasan, Andrea Richardson, Yihong Wang, Ewa Chmielik, Jane Brock, Douglas B. Johnson, Justin Balko, Stephan Wienert, Veerle Bossuyt, Stefan Michiels, Nils Ternes, Nicole Burchardi, Stephen J. Luen, Peter Savas, Frederick Klauschen, Peter H. Watson, Brad H. Nelson, Carmen Criscitiello, Sandra O'Toole, Denis Larsimont, Roland de Wind, Giuseppe Curigliano, Fabrice Andre, Magali Lacroix-Triki, Mark van de Vijver, Federico Rojo, Giuseppe Floris, Shahinaz Bedri, Joseph Sparano, David Rimm, Torsten Nielsen, Zuzana Kos, Stephen Hewitt, Baljit Singh, Gelareh Farshid, Sibylle Loibl, Kimberly H. Allison, Nadine Tung, Sylvia Adams, Karen Willard-Gallo, Hugo M. Horlings, Leena Gandhi, Andre Moreira, Fred Hirsch, Maria V. Dieci, Maria Urbanowicz, Iva Brcic, Konstanty Korski, Fabien Gaire, Hartmut Koeppen, Amy Lo, Jennifer Giltnane, Marlon C. Rebelatto, Keith E. Steele, Jiping Zha, Kenneth Emancipator, Jonathan W. Juco, Carsten Denkert, Jorge Reis-Filho, Sherene Loi, Stephen B. Fox
ADVANCES IN ANATOMIC PATHOLOGY
(2017)